Pharmacokinetic Variability

PK Variability Intro - Diverse Drug Drama

• Core Concept: Significant inter-individual or intra-individual differences in how the body handles drugs (Absorption, Distribution, Metabolism, Excretion - ADME processes).
• Clinical Consequence: "One dose fits all" often fails. Leads to:
  • Therapeutic failure (sub-optimal effect)
  • Unexpected toxicity (adverse drug reactions - ADRs)
• Primary Aim: To understand and predict these variations for personalized medicine, optimizing efficacy and safety.
• Major Influencers: Genetic makeup, physiological states (e.g., age, pregnancy), pathological conditions (e.g., renal/hepatic disease), drug-drug interactions.

⭐ For drugs with narrow therapeutic indices (e.g., Warfarin, Lithium, Digoxin), even minor PK variations can have major clinical consequences, necessitating Therapeutic Drug Monitoring (TDM).

Intrinsic Factors - Born This Way

• Genetics (Pharmacogenomics): Key determinant of variability.
  • Enzyme polymorphisms:
    • CYP450 (e.g., CYP2D6, CYP2C19, CYP2C9): Affect metabolism of codeine, clopidogrel, warfarin.
    • TPMT: Azathioprine toxicity risk.
    • NAT2: Isoniazid (slow vs. fast acetylators).
    • UGT1A1: Irinotecan toxicity.
  • Receptor/Transporter variations (e.g., P-glycoprotein).

  ⭐ CYP2C19 loss-of-function alleles significantly reduce clopidogrel's antiplatelet effect, increasing risk of cardiovascular events post-PCI.

• Age:
  • Neonates/Infants: Immature hepatic/renal function, ↑ total body water. Dose adjustments critical.
  • Elderly: ↓ organ function (renal, hepatic), ↓ lean mass, ↑ fat, polypharmacy. Often require ↓ doses.
• Sex/Gender:
  • Differences in body composition, hormones, enzyme activity (e.g., alcohol dehydrogenase).
  • Pregnancy: Altered Vd, protein binding, metabolism, excretion.
• Race/Ethnicity:
  • Variations in allele frequencies (e.g., CYP2D6, VKORC1).
  • Example: Higher warfarin sensitivity in some Asian populations.

Extrinsic & Disease - Life's Curveballs

• Drug-Drug Interactions (DDIs):

  • Enzyme Induction (e.g., Rifampicin - 📌 PCRAPS): ↓ drug effect.
  • Enzyme Inhibition (e.g., Ketoconazole - 📌 SICKFACES.COM Group): ↑ drug toxicity.
  • Protein Binding Displacement (e.g., Warfarin + Aspirin): ↑ free drug.

• Food-Drug Interactions:

  • Altered absorption (Tetracycline + dairy ↓; Griseofulvin + fat ↑).
  • Grapefruit juice: Potent CYP3A4 inhibitor.

• Environmental Factors:

  • Smoking (CYP1A2 induction): ↓ theophylline levels.
  • Alcohol: Acute inhibition, chronic induction of metabolism.

• Disease States Impacting PK:

  • Renal Disease:
    • ↓ GFR → ↓ drug excretion (e.g., Aminoglycosides, Digoxin).
    • Dose adjustment often based on $CrCl = \frac{(140 - Age) \times Wt_{kg}}{72 \times SCr_{mg/dL}} (\times 0.85 \text{ if female})$.
  • Hepatic Disease:
    • ↓ Metabolism (esp. high extraction drugs like Propranolol). ↓ Albumin → ↑ free drug (e.g., Phenytoin).
    • Child-Pugh score guides dosing.
  • Cardiac Disease (Heart Failure):
    • ↓ Cardiac Output → ↓ tissue perfusion → ↓ drug distribution & elimination.
  • Thyroid Disease:
    • Hyperthyroidism: ↑ metabolism/clearance.
    • Hypothyroidism: ↓ metabolism/clearance.

⭐ Severe liver disease significantly ↑ bioavailability of high first-pass metabolism drugs (e.g., propranolol, morphine); dose reduction is vital.

Managing Variability - Tailored Therapy Tactics

• Therapeutic Drug Monitoring (TDM):
  • Essential for Narrow Therapeutic Index (NTI) drugs (e.g., Digoxin, Lithium, Phenytoin, Aminoglycosides, Vancomycin).
  • Aims: Optimize dose for max efficacy, min toxicity.
• Dose Individualization Strategies:
  • Patient factors: Age, weight, renal (CrCl), hepatic function.
  • Pharmacogenomics (PGx): Genotype-guided dosing (e.g., Warfarin & CYP2C9/VKORC1).
  • Population PK (PopPK) models: Guide initial dosing & subsequent adjustments.
• Adjustments in Special Populations:
  • Pediatrics: Dose by mg/kg or BSA; consider developmental PK variations.
  • Geriatrics: "Start low, go slow"; manage polypharmacy, expect reduced clearance.
  • Pregnancy: Significant ADME alterations necessitate careful dose selection.
  • Obesity: Drug lipophilicity impacts Vd; use appropriate weight metric for dosing.

⭐ Phenytoin: Saturable kinetics; small dose ↑ near saturation → large plasma concentration ↑ & toxicity. TDM vital.

High‑Yield Points - ⚡ Biggest Takeaways

• Genetic polymorphisms (e.g., CYP2D6, NAT2) cause major variations in drug metabolism.
• Age extremes (neonates, elderly) significantly impact drug ADME.
• Renal and hepatic disease necessitate dose adjustments due to altered drug clearance.
• Drug interactions, especially CYP enzyme induction/inhibition, are key variability factors.
• Pregnancy modifies pharmacokinetic parameters like Vd and clearance.
• Obesity alters distribution of lipophilic drugs and overall drug disposition.
• Therapeutic Drug Monitoring (TDM) is vital for drugs with narrow therapeutic windows and high variability.